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1. Introduction
1.1. Melanocytic tumours
Melanocytic tumours derive from melanoblast and melanocyte transformation and occur both
in humans and dogs [1-4]. These lesions are mainly found at skin, digits and oral cavity and
eye [2,5,6]. Moreover, melanocytic tumours can be benign or malignant. Melanomas are
aggressive tumours that can metastasize early in the course of the disease, both locally and in
distant organs [3,7,8]. Whereas in mouth and eye, this type of tumour is generally malignant,
at cutaneous level, and despite the difficulties of making a precise diagnosis, melanocytic
tumours are usually benign. When malignant, they are very aggressive [3-5,8,9].
Generally, the tumour initially starts with a radial-growth phase, which can rapidly progress
to a vertical-growth phase, a stage where melanoma cells have a high proliferation rate and a
strong ability to metastasize [10]. Although early detection and improved surgical techniques
had increase the patient survival, the prognosis of metastatic melanoma is still very poor due
to the resistance to existing therapies [10,11]. Consequently, cutaneous melanoma, the most
malignant tumour of the skin, still represents the leading cause of skin cancer deaths [10];
therefore, canine malignant melanoma is a life threatening disease, with up to 80% of affected
dogs developing metastasis [12].
The similarities between human and canine melanoma, coupled with their similar environ‐
mental exposure, make spontaneous canine melanoma an excellent model in comparative
pathology, for studying the correspondent disease in human counterpart [8,13-15]. These
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studies rely, primarily, on understanding the factors and mechanisms underlying tumour
growth and dissemination, which, ultimately, allows the design and effective use of novel
therapeutic strategies for cancer therapy [4,10,11,16].
The major hallmarks of cancer include migration, invasion, metastasis and angiogenesis [17].
An event intrinsically associated with the initial process of tumour invasion is similar to the
epithelial-mesenchymal transition (EMT), a highly conserved and fundamental process of
morphological transition that occurs during developmental processes; during this event,
epithelial cells down-regulate cell–cell adhesion molecules and acquire a mesenchymal
phenotype with reduced intercellular interactions and increased migratory capacity [17,18].
In addition, for cancer cells being able to continue growing and start migrating, new blood
vessels have to be created by angiogenesis, being the new vessels easily penetrable by tumour
cells due to their elevated permeability and reduced resistance [17-21].
Under normal circumstances, the extracellular matrix (ECM) constitutes one of the natural
barriers against tumour spread [11,22-24]. Therefore, as cell dissemination from the primary
tumour includes invasion of surrounding tissue and basement membranes, intravasation into
the lymphatic or blood circulation, adhesion and extravasation into distant organs, degrada‐
tion and remodeling of ECM by proteolytic enzymes are essential for tumour metastasis
[5,17-19,25,26]. Thus, proteolytic enzymes have been considered important factors and
potential molecular markers associated with tumour growth and invasion in several types of
cancer, including melanoma [16,26,27], where prognostic markers are needed to predict the
risk of progression, assess the clinical outcome and select optimal treatment strategies [4,10,16].
1.2. Matrix metalloproteinases
Proteolytic enzymes can be classified as exopeptidases or endopeptidases, based on their
ability to cleave terminal or internal peptide bonds, respectively [28]. Proteases are proteolytic
enzymes present in all organisms in different sizes, shapes and catalytic properties, but with
the common ability to hydrolyze the internal bonds of various peptides [27,29].
Most proteases are classified as serine, cysteine, aspartic or matrix metalloproteinases (MMPs),
according to their catalytic mechanism and inhibitor sensitivities [28,30]. The MMPs or
matrixins were first described in 1962 by Gross and Lapiere [22,23] and are mostly known by
their ability to degrade components of the ECM. This family of endoproteases has been
considered essential in a number of normal physiologic processes as well as pathological
events [24]; therefore, over the last years, the structure and function of MMPs and their roles
in pathological processes, including cancer, have been intensively investigated in both human
and veterinary medical research [19,27,29,31,32].
Currently, more than 25 different types of MMPs have been identified among vertebrates and
the majority is expressed and has similar functions both in humans and dogs [16,27-29,33].
Nevertheless, MMPs have many similarities in their structure, sharing considerable homology
within their major domains, including signal peptide, propeptide, catalytic and hemopexin-
like domains [16,23,27,34]. Additionally, MMPs are zinc- and calcium-dependent for func‐
tional activity and, according to substrate specificities, domain organization and sequence
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similarities, they are classified into six groups: collagenases, stromelysins, matrilysins,
membrane-type MMPs (MT-MMPs), gelatinases and other MMPs [16,23,27,35].
Collagenases are represented by MMP-1, MMP-8 and MMM-13 or collagenase -1, -2 and -3,
respectively. Preferentially, they have affinity to collagen types I, II and III. Stromelysins are
represented by MMP-3 and MMP-10 or stromelysin-1 and -2, respectively; they have specificity
for laminin, fibronectin, elastin, gelatin and proteoglycans (MMP-11 is called stromelysin-3
but it is usually grouped with “other MMPs”). Matrilysins are represented by MMP-7 and
MMP-26 or matrilysin-1 and -2, respectively; they have specificity for collagen IV, fibronectin,
elastin and gelatin. The MT-MMPs are MT1, 2, 3, 4, 5 and 6 – MMP or MMP-14, -15, -16, -17,
-24, and -25, respectively; they have specificity for collagen, gelatin, fibronectin and laminin
[16,19,27,35,36]. Finally, the group of gelatinases includes MMP-2 and MMP-9 or gelatinases
A and B, respectively. Gelatinases have a fibronectin domain into the catalytic site, which
improves the degradation of denatured collagen (gelatin), type IV (basement membrane)
collagen, type V collagen, fibronectin, plasminogen and elastin. The MMP-2, unlike MMP-9,
digests type I, II, and III collagens [16,19,28,35].
There are a variety of cells expressing gelatinases. Typically, MMP-2 is produced by macro‐
phages, T-cells, osteoblasts, endothelial and epithelial cells, fibroblasts, keratinocytes and
chondrocytes. On the other hand, MMP-9 expression occurs in T-cells, neutrophils, leukocytes,
endothelial and breast epithelial cells, osteoclasts, keratinocytes, monocytes, macrophages,
and in connective tissue cells [19,23,30,37]. Furthermore, and despite their usual extracellular
activity, several MMPs have been demonstrated as active proteases localized in nuclei of
various human and animal cell types, including heart myocytes, brain neurons, breast and
endothelial cells, fibroblasts and hepatocytes [26].
The degradation of ECM by MMPs essentially consists in the disruption and remodeling of
structural barriers that enable the occurrence of extravascular tissue access and cellular
invasion into the surrounding tissue stroma [22,23,38]. However, that process is more complex
as it makes the ECM a major influence of cell behavior survival and communication, since it
responds to signaling molecules and acts as ligand for cellular adhesion receptors [24,27,28].
Therefore, as MMPs alter and structurally organize ECM, thus altering matrix-derived signals,
they are essential to sustain homeostasis, regulating several cellular processes that require
ECM breakdown and modification, such as cell shape, movement, growth, differentiation,
survival and apoptosis [16,19,28,34].
Generally, both MMP-2 and -9 participate in these processes, where MMP-2 has major roles
reducing cell adhesion, stimulating cell migration and differentiation and acting as an anti-
inflammatory factor; the MMP-9, on the other hand, may act as anti- or pro-inflammatory factor
[35]. The gelatinases are also linked to the cell spreading and cytoskeletal changes during cell
migration [19]. Moreover, MMPs substrates are not limited to ECM proteins; in fact they have
the ability to cleave and activate one another, disrupt cell–cell contacts and cleave latent growth
factors, proteinases and their inhibitors, blood clotting factors, cell surface receptors, adhesion
molecules and intracellular substrates [19,24,28,34,39]. Therefore, MMPs, including gelatinas‐
es, are associated with many normal physiological events, such as embryonic development,
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reproduction, ovulation, wound healing, bone resorption, tissue morphogenesis, nerve growth
and mammary gland development [16,23,30,34,38].
Usually, alternating cycles of proteolysis and its inhibition prevent an excessive proteolytic
activity and tissue destruction [19]. Therefore, in most tissues, basal MMP production is
normally very low [23,28,39]. The MMP-2, in particular, is widely distributed and is constitu‐
tively expressed by most cells with only modest up or downregulation under various condi‐
tions [19,29]; on the other hand, MMP-9 expression is normally induced and, while almost
MMPs are constitutively secreted after their translation [29,30], MMP-9 can be packaged in
neutrophils, being released during specific stimulation [19,23,26,30]. Nevertheless, endothelial
cells can release both MMP-2 and -9 very quickly, indicating that they might originate from
intracellular storage compartments [26].
At the transcription level, the expression of MMPs can be activated by cytokines and growth
factors, including transforming growth factor-α and -β (TGF- α and β, respectively), tumour
necrosis factor- α (TNF- α) interleukins (ILs), interferons, endothelial growth factor (EGF),
basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), nerve growth factor
(NGF) and vascular endothelial growth factor (VEGF), among others [17,18,23,24,28]. In
addition to soluble proteins, cell-matrix and cell-cell interactions, mediated by cell-adhesion
molecules like epithelial (E)-cadherin and several integrins [21], can also stimulate the
expression of MMPs [23]. At the post-transcriptional level, gene expression can be regulated
through the stability of mRNA in the cytoplasm [30]. On the other hand, the expression of
MMPs can be downregulated by targeting of extracellular components, intracellular growth
factors, signal transduction pathways and suppressive factors, which include transforming
growth factor-beta (TGF-β), retinoic acids and glucocorticoids [19,23,24,26].
Gelatinases are secreted into the ECM in an inactive or latent form, being called proenzymes
or zymogens; the proenzyme secretion, activation and the inactivation of their activities by
endogenous inhibitors represent additional regulation processes of these enzymes
[18,19,23,30]. Initially, each MMP contains an amino-terminal (N-terminal) domain, called pre-
domain, a signal sequence that guides the enzyme for synthesis and secretion in the extracel‐
lular environment in a zymogenic form; when that occurs, the pre-domain is lost and the
latency of these enzymes is maintained by the cysteine in the pro-domain of the propeptide,
which chelates the zinc ion bounded in the active site, formatting a bridge. This interaction can
be further abolished by mechanical disruption or other processes (cysteine switch) leading to
an intermediate activation, which is followed and completed by the activity of other extracel‐
lular proteases, including other MMPs, or even by autocatalytic cleavage; at the time of enzyme
activation, the pro-domain is removed [16,23,35,38].
In both humans and dogs, pro-MMP-2 has 72 kDa and may be converted to the 62 or 66 kDa
active forms by several enzymes, such as MMP-1,MMP -7, MMP-14, MMP-15, MMP-16,
MMP-24, MMP-25, thrombin and plasmin; on the other hand, MMP-2 can activate MMP-1,
MMP-13 and MMP-9. In addition to MMP-2, pro-MMP-9 (92 kDa) can be activated to the 82,
84 or 88 kDa active form by MMP-3, MMP-7, MMP-10, MMP-13, MMP-26 and plasmin
[19,28,29,35]. In the particular case of MMP-9, the substrate binding to proenzime seems to be
enough to trigger the cysteine switch. This may explain the fact that usually, the active MMP-9
Melanoma - From Early Detection to Treatment / Book 24
is often absent in the tissues, despite the observation of its catalytic activity [19]. Furthermore,
MMP-9 exists in plasma as a monomer, complexed as a dimer with a protein named lipocalin,
present in activated neutrophils; the MMP-2, on the other hand, is strictly monomeric [19].
Moreover, except for matrilysin, all MMPs also have a hemopexin domain, which is a heme-
binding peptide at the carboxyl-terminal (C-terminal) [16,23,27,29]. This additional domain is
important in substrate recognition and in inhibitor binding [16,27]. The MMPs activity can be
inhibited by zinc- and calcium-chelating agents and by specific naturally occurring tissue
inhibitors of metalloproteinases (TIMPs), which augment cell adhesion and stabilize cell–cell
contacts by inhibiting ECM degradation [16,19,23,26]. The TIMPs are secreted proteins, but
may be found at the cell surface in most tissues and body fluids, in association with membrane-
bound proteins; based on structure, four different types of TIMPs have been characterized:
TIMP-1, -2, -3 and -4 [16,28,30,34].
Both TIMP-1 and TIMP-2 inhibits MMP-9, although TIMP-1 is more effective; on the other
hand TIMP-2 inhibits proMMP-2 over 10-fold more effectively than TIMP-1. However, TIMP-2
has a bi-functional effect on MMP-2, inhibiting its activity in high concentrations, but regu‐
lating its activation when present in low levels, by associating to MT1-MMP and pro-MMP-2
at cell surface [28,30,34,38,39]. Like TIMP-1 and TIMP-2, TIMP-3 and TIMP-4 also may inhibit
MMP-2 and -9; TIMP-4, particularly can also regulate MMP-2 by inhibiting its activator MT1-
MMPs [30,34]. In addition, gelatinases, unlike other families, can be regulated by TIMPs before
being activated, since these inhibitors can reversibly bind to MMP-2 and -9 zymogens [34,37].
Like MMPs, TIMPs also exhibit biological functions, including mitogenic activities on a
number of cell types, which are independent of their MMP-inhibitory activities; therefore,
TIMPs are also important regulators in cellular activities [34,38].
Another pos-translation regulation mechanism of MMPs activity is associated with their
localization, where specific events concentrate proteinases in the pericellular microenviron‐
ment, within the vicinity of their targets [18,26,28,34]. These localization mechanisms also limit
the access of TIMPs and the extent of proteolysis to discrete regions [19,26,28].
However, as a result of specific protein, genetic and/or epigenetic mutations [23,27-30], and
reactive oxygen species influence [18], the functions of MMPs that are essential in normal
conditions may develop into pathogenesis. When the regulatory mechanisms are compro‐
mised, MMPs production and activity may be abnormally diminished or increased, leading to
an improperly ECM degradation [16,23,34,40,41]. Therefore, the occurrence of MMPs dereg‐
ulation, particularly an increased gelatinase activity [16,19,34,39], is frequently associated with
several human and canine pathological events, including: rheumatoid arthritis, inflammatory
disorders of the gastrointestinal tract, cerebrovascular, cardiovascular, skin and lung diseases,
and cancer [16,18,19,24,27,29,32].
1.3. Matrix metalloproteinases and cancer
The MMPs have been implicated in cancer for more than 40 years [18], being overexpressed
in a wide range of malignant tumours in response to oncogenic cellular transformation [23,26],
cytokines and several growth and angiogenic factors [16,19,23,26,42]. In addition, the com‐
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plexity of the tumour microenvironment triggers a variety of regulatory cascades that
determine the expression and function of several proteins; therefore, the tumour context is
important, that is weather TIMPs and/or activating enzymes in the microenvironment are
present or not [18].
Despite they are often produced by invasive cancer cells, most MMPs, under stimulation of
ILs and growth factors, are produced by non-malignant stromal cells such as fibroblasts,
endothelial cells and bone marrow-derived cells, including macrophages [5,17,19,21,43].
Furthermore, MMPs are typically required in the early stage of the tumour progression [19,20]
due to their ability to degrade the ECM, basement membranes, growth-factor receptors,
cytokines, chemokines, cell adhesion molecules, apoptotic ligands and angiogenic factors [17,
27,33], since that contributes to tumour proliferation, invasion, intravasation into circulation,
extravasation, migration to metastatic sites and angiogenesis [16,19,21,26,27]. Therefore,
several proteins, including MMPs, integrins, matrix proteins are gathered when the cells need
to invade and migrate and come across a non-degraded ECM [19].
On the other hand, MMPs may deregulate the balance between growth and antigrowth signals
in the tumour microenvironment [18,20,44]. Additionally, MMPs orchestrate inflammation,
which is linked to cancer progression [18,19,43], and are also associated with mechanisms that
cancer cells develop to avoid host immune response, mainly through the suppression of T-
lymphocytes proliferation or by decreasing the tumour cells sensitivity to natural killer (NK)
cells [19,23,25,26,31]. The MMP function is also involved with the ability of malignant cells to
evade apoptosis, by cleaving ligands and receptors that transduce pro-apoptotic signals
[18,23,24]. Furthermore, the overexpression of MMPs, gelatinases in particular, can also cause
EMT and induce genomic instability [17,18]. Consequently, the presence of MMPs in malignant
diseases, including gelatinases, is often correlated with highly aggressive tumours and low
prognosis, both in humans and dogs [18,27,32,43,45].
However, the degradation of ECM components and other extracellular molecules, although
under malignant stimulation, may generate fragments with new bioactivities that inhibit
angiogenesis [18]. On the other hand, TIMPs expression in tumour tissue and stroma generally
inhibits tumour cell growth, reduces the invasive and metastatic capacity of tumour cells and
prevents angiogenesis [16,34,42,46,47]. Hence, it would be logical to assume that during cancer
development, an high MMP:TIMP ratio would be present [44]. However, an excessive activity
of MMPs may difficult tumour cell adhesion by destroying cell-matrix interactions or matrix
signals required for cell migration, invasion and angiogenesis; therefore, even in cancer
progression, a certain balance between MMPs and TIMPs is needed, in order to allow the
remodeling of stromal tissues [19,20,26,44].
Among all MMPs, the gelatinases and respective proenzymes are two of the most important
members in the development and invasion of tumour cells in several neoplasias. Both MMP-2
and MMP-9 are expressed in a variety of human [16,19,25,27,43,48] and canine [32,33,45,49-52]
cancers, including lymphoma, glioma, ovarian, lung, bladder, pancreatic, prostate, renal, oral,
gastric, and breast cancers, neuroblastoma, promyelotic leukemia, fibrosarcoma, osteosarco‐
ma, cutaneous mast cell tumours and melanoma.
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With respect to balance deregulation between growth and anti-growth signals, as MMPs
substrates,  latent  growth factors  can be  activated by gelatinases  [20].  For  instance,  they
are able to release the active TGF-β, thus promoting angiogenesis and tumour metastasis
[4,17-19,44]; on the other hand, TGF- β up-regulates the MMP-2, acting as a strong auto‐
crine  mediator  of  tumour  cell  invasion [4].  Moreover,  neutrophil-derived pro-MMP-9  is
not complexed with TIMP-1, being more readily activated to drive tumour angiogenesis
by  activating  the  basic  fibroblast  growth  factor  2  (FGF-2)  pathway  [17,18].  Likewise,
MMP-9  is  implicated  in  vasculogenesis  and  regulates  the  bioavailability  of  bFGF  and
VEGF, the most potent inducer of tumour angiogenesis, which may also affect lymphan‐
giogenesis [17-19,43,45]. The increased expression of MMP-2 is also associated with lym‐
phatic invasion and lymph node metastases [18].
Additionally, not only the presence of MMPs, but also their cellular location plays a crucial
role in cell invasion [53]; during invasion, the localization of MMPs to specialized cell surface
structures is requisite for their ability to promote invasion [17]. Thus, the cell surface-bound
gelatinases also play a role in cancer progress; in leukemic cells, for example, pro-MMP-9
interacts with intercellular adhesion molecule-1 (ICAM-1), enhancing tumour cell resistance
to NK cell-mediated cytotoxicity [19,25,26]. Furthermore, the gelatinases cell surface activity
has been found to be dependent of cell adhesion molecules, such as integrins, for tumour
migration, invasion angiogenesis in many cancers [5,10,19,23,26,28].
In human melanoma cells, particularly, MMP-2 and -9 have been focus of attention in the last
years, both in cutaneous [4,5,27,43,48,53-57], as well as in eye [11,58-62] and oral melanoma [6].
Although the role of MMPs in melanoma remains controversial [5,55], both gelatinases are
often overexpressed in melanocytic tumours, frequently in advanced stages of melanoma, thus
being associated to the most invasive and aggressive cases and to a low prognosis and patient
outcome. The specific activation processes and the localization of MMPs during migration of
melanoma cells is still poorly understood [5]; nevertheless, MMP-2 and -9 have been detected
in a high number of vesicular organelles, which may be a way of achieving a rapid and
directional proteolysis during cell migration, invasion and angiogenesis [26]. In veterinary
medicine, as the best authors’ knowledge only two studies concerning the gelatinases expres‐
sion have been made in canine melanocytic tumours, one in cutaneous lesions [49] and the
other in oral melanomas [51].
Conversely to the majority of the observations, there are several MMPs, including gelatinases,
with the ability to negatively control some aspects of cancer progression. Particularly, MMP-2
and -9 are able to cleave plasminogen, which creates angiostatin, and MMP-9 can also cleave
a basement membrane collagen type XVIII, creating a product named endostatin; both
cleavage products can inhibit endothelial cell proliferation and angiogenesis [20,22,27,38,44].
Similarly a few studies indicate a positive correlation between increased TIMP levels and poor
outcome in some human malignancies [40]. Although the significance of this event remains
unclear, it seems that the role of each MMP and TIMP depends on the type of cell that produces
the enzyme (tumour cell or stroma), the cancer stage, the tumour site (primary or metastasis),
the substrate profile, the tissue of neovascularization and several microenvironmental factors
[17-20]; however, the significance of this event remains unclear [20,27,44].
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In the context of cancer therapy, several clinical trials have been developed in both humans
and dogs, in order to inhibit MMP activity [18,32,52], particularly the activity of gelatinases,
in several malignant diseases, including melanoma [27,42]. The majority of these studies are
based on the use of TIMPs or synthetic inhibitors [20,26,27,42] and knockout experiments [19,
42], where MMP-2 and MMP-9 are absent. In addition, similar studies are based on the
degradation of particular cell receptors that bind to gelatinases [19]. Although some these
inhibition studies remain controversial, promising results have been observed, including the
reduction of the growth and invasion of the more aggressive cases [19-21,26,27]. The presence
of anti-tumour MMPs may be the underlying cause of lack of success of some of these clinical
trials [27]; therefore, the dual role of MMPs in angiogenesis highlights the need to develop
selective MMP inhibitors [20].
On the bases of what was previously described, MMPs are undeniably important factors
influencing tumour behavior; however, there is still not enough knowledge about the function
of individual MMPs in cancer [19,27]. As the dog has been considered a good model for studies
of spontaneous melanoma [8,13-15] and since the role of MMPs in canine melanocytic tumours
is still poorly explored and understood, the aims of the present work are to study the immu‐
noexpression of MMP-2 and MMP-9 in canine cutaneous melanocytic tumours and the
association between them and several pathological characteristics.
2. Material and methods
2.1. Tissue processing and tumour classification
From the archive of the Histopathology Laboratory of the University of Trás-os-Montes and
Alto Douro, 42 canine cutaneous melanocytic tumours and 5 normal skin samples were
obtained. These tumours were excised from dogs presented for treatment at the Veterinary
Teaching Hospital of the University of Trás-os-Montes and Alto Douro and several other
veterinary private clinics. The anonymity of the sample sources was respected.
The samples were fixed in 10% buffered formalin and paraffin embedded. For the histopatho‐
logic study, 4-µm-thick tissue sections were stained with hematoxylin and eosin, with and
without melanin blanching, depending on the amount of pigment. The blanching was
performed by slide incubation in 0,25% potassium permanganate for 30–60 minutes and 0,1%
oxalic acid for 5–8 minutes. Each sample was re-examined by two independent pathologists
(IP and JP) in order to confirm the diagnosis, according to the World Health Organization
International Histological Classification of Tumours of Domestic Animals criteria [63]. All
slides were taken into consideration for this study and complete sections of the tumours were
fully analysed.
2.2. Histopathological evaluation
The following pathological features were evaluated: histological type - melanocytoma
(benign), melanoma (malign); presence of ulceration; presence of necrosis; mitotic index;
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nuclear grade; degree of pigmentation, presence of aberrant tumoural cells; stroma; and
tumoural vascular invasion. Mitotic index was calculated by counting all the mitosis present
in 10 high power fields (HPF) (400x): mitotic index I (<3 mitosis in 10 HPF); mitotic index II
(3–5 mitosis in 10 HPF) or mitotic index III (>5 mitosis in 10 HPF). For nuclear grade, the
following grades were defined: nuclear grade I when the nuclei had minimal variations in their
shape and size compared to normal nuclei; nuclear grade II consisted of moderate alterations
of nuclear shape; and nuclear grade III consisted of the nuclei that were irregular and larger
than normal [64].The degree of pigmentation was estimated using a subjective scale from scant
(pigment in fewer than 30% of cells), moderate (pigmentation in 31–80% of cells), and abundant
(pigment in more than 80% of cells). The amount of stroma was categorized in: scant, moderate,
and abundant [65].
2.3. Immunohistochemistry
For immunohistochemical studies, 3-µm sections were cut from each specimen and mounted
on silane-coated slides. MMP-2 and MMP-9 immunoexpression were carried out by the
streptavidin-biotin-peroxidase complex method, with a commercial detection system (Ultra
Vision Detection System; Lab Vision Corporation) following the manufacturer’s instructions,
with and without blanching. All the washes and dilutions were made in phosphate buffered
saline (PBS) solution (pH=7.4).
Sections were deparaffinized in xylene and rehydrated in a graded alcohol series, ending in
tap water. The blanching was performed with 0,25% potassium permanganate (KMnO4) and
0,1% oxalic acid (H2C2O4). For MMP-2, antigens were retrieved by microwave treatment for
20min at 750W in a solution of citrate buffer, in distilled water. No pre-treatment was used for
MMP-9 labeling.
After cooling the slides at room temperature, endogenous peroxidase was blocked, through
the incubation with 3% hydrogen peroxidase for 30min. Slides were then dried and sections
outlined with a hydrophobic pen (Liquid Blocker, Daido),washed in PBS for 5min and applied
the blocking serum for 5min (Ultra VBlock, Labvision Corporation). Subsequently the sections
were incubated overnight at 4 ◦C, with the primary antibodies: MMP-2 (Neomarkers) diluted
1:150 and MMP-9 diluted 1:200 (Neomarkers) in phosphate buffered saline (PBS; pH 7,4; 0,01
M). On the following day, sections were washed in PBS for 5min, at room temperature, and
then applied biotinylated serum and streptavidine peroxidase for 10min each (both included
in the kit Ultravision Detection System, Labvision Corporation), with intermediate washings
in PBS, for 5min. Immunolabeling was observed by incubation with 3,3-diaminobenzidine
tetrahydrochloride (DAB; SIGMA) 0,05% with 0,01% H2O2 for 5min. After washing in distilled
water, the sections were counterstained with Gill haematoxylin, dehydrated, cleared and
mounted. Each set of staining included a known positive control. The primary antibody was
replaced by PBS and by an irrelevant antibody for negative controls
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2.4. Immunohistochemistry evaluation
Positivity was indicated by the presence of distinct brown cytoplasmic labeling. Each specimen
was evaluated in a blinded manner by 2 independent investigators (IP e FLQ). The interob‐
server variability was low; in case of discrepancy, a consensus was reached among 3 observers.
The number of malignant cells expressing MMP-2 and MMP-9 was assessed using a semi‐
quantitative scale by estimating the percentage of positive tumoural cells (labeling extension).
A 4-grade scale was used: negative,0,<5%; 1, 5-20% of positive cells; 2, 21–49%; and 3, over 50%
of positive cells (adapted from [57]). The labeling intensity was recorded as: negative (0); weak
(+); moderate (++) and strong (+++).
2.5. Statistical analysis
Statistical analyses were made to determine correlation between MMPs immunoexpression
(labeling extension and intensity) and tumor diagnosis (benign or malignant), and between
MMPs immunoexpression in malignant melanomas and the pathological variables under
study. The statistical software SPSS (Statistical Package for Social Sciences, IL, USA), version
12.0, was used for statistical analysis. We performed a chi-square test (χ2) for studying
categorical variables. In all statistical comparisons, p< 0.05 was accepted as denoting significant
differences.
3. Results
3.1. Tumours
The studied canine cutaneous melanocytic tumours were originated from dogs of different
breeds. Undefined breed (n=13/42), Boxer (n=11/42), Rottweiller (n=5) and Cocker Spaniel (n=2)
were most commonly represented. The age of the animals ranged from 9 months to 15 years,
with an average of 10 years. Twenty dogs were female and 22 were male.
The lesions occur as nodules solitaries, occasionally ulcerated, varying in size between 0,4-9
cm (average of 2,7cm).
From the 42 tumours included in the study, 11 cases were classified as melanocytomas (benign
tumours) and 21 cases as malignant melanomas.
3.2. MMP-2 and MMP-9 expression in canine cutaneous melanocytic tumours
Five samples of normal skin and 42 melanocytic tumours were examined (Table 1). Occasional
dermal fibroblasts and macrophages were positive for both MMP-2 and MMP-9 in normal skin
and tumours.
Intracytoplasmic immunostaining for MMP-2 and MMP-9 immunoreactive protein was found
in epidermal and dermal nests of tumoural cells, both centrally and peripherally. Positive cells
were homogeneously distributed without any constant increase in invasive fronts.
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Sample nº HistologicalClassification
MMP-2 MMP-9
Extension Intensity Extension Intensity
1 Melanoma 3 +++ 1 +
2 Melanocytoma 3 ++ 2 ++
3 Melanocytoma 2 +++ 0 0
4 Melanoma 3 +++ 1 +
5 Melanocytoma 3 +++ 3 +
6 Melanocytoma 3 ++ 0 0
7 Melanoma 2 + 2 ++
8 Melanoma 1 ++ 1 +
9 Melanoma 1 ++ 2 ++
10 Melanoma 3 + 3 +++
11 Melanoma 2 + 3 +
12 Melanoma 2 + 3 +++
13 Melanoma 3 ++ 2 ++
14 Melanoma 1 + 3 ++
15 Melanoma 1 + 3 ++
16 Melanocytoma 3 ++ 0 0
17 Melanocytoma 3 ++ 3 +
18 Melanoma 1 + 3 +++
19 Melanoma 2 ++ 2 ++
20 Melanoma 3 + 3 ++
21 Melanoma 2 + 1 +++
22 Melanocytoma 3 ++ 0 0
23 Melanocytoma 3 ++ 2 +
24 Melanocytoma 3 ++ 2 +
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Sample nº HistologicalClassification
MMP-2 MMP-9
Extension Intensity Extension Intensity
25 Melanoma 1 ++ 2 ++
26 Melanoma 3 ++ 2 ++
27 Melanoma 2 ++ 1 +
28 Melanocytoma 3 +++ 2 +
29 Melanocytoma 3 +++ 2 +
30 Melanoma 2 ++ 1 +
31 Melanoma 1 + 1 +
32 Melanoma 3 + 3 +++
33 Melanoma 1 + 1 ++
34 Melanoma 2 + 1 +
35 Melanoma 2 + 3 ++
36 Melanoma 1 + 3 +
37 Melanoma 1 ++ 3 ++
38 Melanoma 2 + 1 ++
39 Melanoma 3 ++ 3 +++
40 Melanoma 3 ++ 3 ++
41 Melanoma 3 + 3 +
42 Melanoma 2 + 1 +
Extension – <5 (0), 5–20% (1), 21–50% (2), >51% of positive cells (3); Intensity - negative (0), weak (+), moderate (++),
strong (+++)
Table 1. MMP-2 and MMP-9 immunoexpression in canine cutaneous melanocytic tumours.
The expression of MMP-2 was observed in all tumours. The percentage of labeled cells ranged
from (1) isolated cells (n=10; 23.8%), to (2) foci of labeled cells (n=12; 28,6%), to (3) diffuse labeled
cells (n=20; 47,6%). With respect to labeling intensity, there was weak positivity (+) in 18 cases
(42,9%), moderate intensity (++) of labeling in 18 cases (42.9%) and strong intensity (+++) in 6
cases (14,3%), which is represented in Figures 1 and 2.
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Figure 1. MMP-2 expression in canine cutaneous melanocytoma: difuse (3) and moderate labelling intensity (++). IHC.
Bar, 30 µm
Figure 2. MMP-2 expression in canine cutaneous malignant melanoma. The positivity is moderate in a 2 extension of
positive cells IHC. Bar, 60 µm
For MMP-9 immunolabeling extension, 16 melanocytic tumours showed a diffuse (3) immu‐
nolabeling (36.1%), and 22 an intermediate labeling (2) pattern represented in Figure 3. Only
4 tumours were negative (9,5%). For labeling intensity, the weak (+) and moderate (++) labeling
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pattern (Figure 3) was most frequently observed (n=17 and n=15 respectively). Six cases
showed a strong (+++) reaction to MMP-9 (Figure 4).
Figure 3. Difuse (3) MMP-9 expression in canine malignant melanoma, with a moderate intensity (++). IHC. Bar, 30 µm
Figure 4. MMP-9 expression in canine malignant melanoma, with a difuse (3) and strong (+++) labelling intensity. The
tumoural cells invades hepatoid perianal gland. IHC. Bar, 120 µm
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3.3. Association between MMP-2 and MMP-9 expression and tumour malignancy
The percentage of MMP-2 positive cells and the intensity of reaction were significantly
different between benign and malignant tumours. Benign tumours (melanocytomas) showed
a higher expression of MMP-2 [both for extension (p=0,003) and intensity (p=0,02)] than
malignant melanomas (Table 2).
Regarding MMP-9, the differences observed between benign and malignant tumours were
statistically significant both for the extension of positive cells (p<0,0001) and for the labeling
intensity (p=0,001). Malignant melanomas generally showed a higher number of positive cells
than benign tumours The melanocytomas did not show MMP-9 or, when present, the immu‐
noexpression was generally weak (Table 2).
Melanocytoma Melanoma Total
p
n % n % n %
MMP-2
Extension
1 0 0% 10 40,7% 10 23,8%
0,0032 1 9,1% 11 40,7% 12 28,6%
3 10 90,9% 10 18,6% 20 47,6%
Intensity
+ 0 0% 18 58,1% 18 42,9%
0,002++ 7 63,6% 11 35,5% 18 42,9%
+++ 4 36,4% 2 6,5% 6 16,3%
MMP-9
Extension
0 4 36,4% 0 0% 4 9,5%
<0,0001
1 0 0% 11 35,5% 11 26,2%
2 5 45,5% 6 19,4% 11 26,2%
3 2 18,2% 14 45,2% 16 38,1%
Intensity
0 4 36,4% 0 0% 4 9,5%
0,001
+ 6 54,5% 11 35,5% 17 40,5%
++ 1 9,1% 14 45,2% 15 35,7%
+++ 0 0% 6 19,4% 6 14,3%
Table 2. MMP-2 and MMP-9 immunoexpression in benign and malignant canine cutaneous melanocytic tumours.
3.4. Association between MMP-2 and MMP-9 and pathological features in canine cutaneous
melanoma
The association analysis between MMP-2 immunoexpression (for labeling extension and
intensity) in malignant melanomas (n=31) and the pathological criteria showed that the
differences observed in labeling extension and intensity were not associated with any param‐
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eter (p>0,05), except for MMP-2 intensity and nuclear grade (p=0,049). Table 3 presents the
pathological variables analyzed and their association with MMP-2 expression in canine
cutaneous malignant melanomas.
Pathological features
MMP-9
Extension
MMP-9
Intensity
1 2 3 p + ++ +++ p
Ulceration
Absent
Present
6
4
3
8
5
5 0,30
10
8
4
7
0
2 0,25
Necrosis
Absent
Present
6
4
6
5
6
4 0,96
10
8
7
4
1
1 0,89
Mitotic index
I
II
III
0
4
6
0
3
8
1
5
4
0,44
0
7
11
1
4
6
0
1
1
0,74
Nuclear grade
I
II
III
3
3
4
1
7
3
2
5
3
0,61
2
4
0
11
6
0
5
1
2
0,049
Degree of pigmentation
Scant
Moderate
Abundant
5
4
1
4
4
3
1
7
2
0,31
6
8
4
3
6
2
1
1
0
0,92
Aberrant cells
Absent
Present
7
3
9
2
7
3 0,77
14
4
8
3
1
1 0,69
Stroma
Scarse
Moderate
Abundant
4
6
0
5
6
0
5
4
1
0,62
8
10
0
6
4
1
0
2
0
0,35
Vascular invasion
Absent
Present
8
2
7
4
7
3 0,71
14
4
8
3
0
2 0,07
Table 3. Association of pathological variables with MMP-2 expression in canine cutaneous malignant melanomas.
MMP-9 labeling intensity presented a statistical significant association with the presence of
necrosis (p=0,032), nuclear grade (p=0,09), and degree of pigmentation (p=0,008). Canine
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melanocytic tumours without necrosis, with a lower nuclear grade and more pigmented,
showed a higher MMP-9 labeling intensity. In respect to MMP-9 extension, a positive associ‐
ation is observed with the degree of pigmentation (p=0,003), where the percentage of MMP-9
positive cells is higher in malignant melanomas with abundant amounts of melanin (Table 4).
Pathological features
MMP-2
Extension
MMP-2
Intensity
1 2 3 p + ++ +++ p
Ulceration
Absent
Present
3
8
2
4
9
5 0,15
2
9
8
6
4
2 0,08
Necrosis
Absent
Present
5
6
6
0
7
7 0,07
3
8
10
4
5
1 0,032
Mitotic index
I
II
III
0
5
6
1
2
3
0
5
9
0,34
0
5
6
1
5
8
0
2
4
0,82
Nuclear grade
I
II
III
1
3
2
5
3
9
5
0
3
0,12
1
4
6
3
9
5
7
1
0
0,009
Degree of pigmentation
Scant
Moderate
Abundant
8
2
1
0
3
3
2
10
2
0,003
8
3
0
2
8
4
0
4
2
0,008
Aberrant cells
Absent
Present
7
4
5
1
11
3 0,59
6
5
12
2
5
1 0,18
Stroma
Scarse
Moderate
Abundant
7
4
0
2
3
1
5
9
0
0,17
7
4
0
5
8
1
2
4
0
0,50
Vascular invasion
Absent
Present
6
5
4
2
12
2 0,23
6
5
11
3
5
1 0,32
Table 4. Association of pathological variables with MMP-9 expression in canine cutaneous malignant melanomas.
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4. Discussion
Cutaneous melanoma is one of the most frequent malignant tumours in younger age people
and is characterized by its high capacity for invasion and metastasis. The incidence of human
cutaneous melanoma is increasing in the U.S.A., Australia, and Europe [66,67]. Among canine
population, the incidence of melanocytic tumours is also increasing. Cutaneous canine
melanocytic neoplasms are usually benign. However, when malignant they could be highly
aggressive metastasizing both locally as in distant organs [2,68-70].
Human cutaneous melanoma may develop de novo from normal melanocytes or from potential
precursor lesions, such as atypical dysplastic nevi or congenital nevi [66,67] but in the dog this
evolution is not well established.
Canine malignant melanoma is resistant to most current therapeutic regimens. The search of
novel therapeutic tools is crucial in the fight against this disease. Furthermore, the similarities
between human and canine melanoma make spontaneous canine melanoma an excellent
disease model for studying the corresponding human disease [14,71].
Much work is currently underway in order to identify specific tumour markers, associated
with malignancy [71-73]. However, more studies are needed to differentiating benign from
malignant canine melanocytic neoplasms or predicting survival times.
The involvement of ECM-degrading enzymes, such as MMPs and serine proteases, during
tumour progression and metastasis is well established [28,30]. During the last few decades, in
both human and veterinary oncology there has been considerable interest in studying MMPs
activity as a possible independent prognostic marker and target for therapeutic options
[19,27,29,31,32]. However, the biological significance of expression of MMP-2 and MMP-9
expression in melanocytic tumours is still poorly understood, presenting conflicting results
regarding the relation of MMP expression and the invasiveness of melanoma cells both in
vitro and in vivo [11,74-76].
In canine melanocytic tumours, studies concerning MMP-2 and MMP-9 expression are very
scarce [49,51], and as far as we know, only one study was performed in cutaneous melanocytic
tumours [49] until present.
Here, we analyzed the expression patterns of MMP-2 and MMP-9 in benign and malignant
canine cutaneous melanocytic tumors and its relation with classical parameters of aggressive‐
ness in malignant melanoma.
In our study, both benign and malignant lesions express MMP-2, according to human
analogous studies [60]. However, MMP-2 labeling was significantly higher in benign melano‐
cytic tumours than in malignant counterpart, contrarily to a previous human study, in wich
MMP-2 expression was higher in malignant lesions [60]. Indeed, in vitro and in vivo studies
suggests that MMP-2 activity could be related to the progression of melanoma and may be
required for melanoma cell invasion and metastasis formation [59,77-79]. In canine cutaneous
melanocytic tumours, Docampo et al. [49] did not observe any differences in MMP-2 expres‐
sion between benign and malignant neoplasias.
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We also observed that, in canine cutaneous malignant melanoma, a higher intensity of the
MMP-2 labeling appears to be associated, in a statistical significant way, with nuclear grade
(p=0,049) but not with other histological features. Interestingly, in dogs, this characteristic
seems to be very accurate in predicting overall behavior in these tumours [80]. Being this,
MMP-2 could be implied in canine melanoma aggressiveness. These data are in agreement
with previous human studies, where the expression of MMP-2 increased notably with
architectural disorder, atypia, and progression to melanoma [81,82]. Additionally, some of
these studies observed a correlation between MMP-2 expression and human melanoma
metastization and prognosis [60,83-86]. Indeed, active MMP-2 regulates VEGF-A in melanoma
cells on a transcriptional level via an integrin αvβ5/phosphoinositide-3-kinase-dependent
pathway. In that context, MMP-2 plays a pivotal role in the autocrine regulation of VEGF-A
expression in melanoma cells, and consequently in angiogenesis [87]. However, in our study,
in spite of the association of MMP-2 and nuclear grade, we observed a lack of a association
with vascular tumoural embolus, that needs to be clarified.
With respect to MMP-9, in our samples, all melanomas expressed this MMP, like described in
human ciliary body melanomas [88]. We also observed significant differences in MMP-9
labeling extension (p<0,0001) and intensity (p=0,001) between benign and malignant tumours.
Malignant tumours had a higher MMP-9 expression as described in a previous study in canine
melanocytic tumours [49]. The differences found in MMP-9 immunoreactivity between benign
and malignant lesions were also similar to the previously described in human melanocytic
neoplasms [89] and lead us to speculate that MMP-9 might be involved in the neoplastic
transformation of canine melanocytic tumours. In human benign pigment cell lesions, MMP-9
was expressed in cellular blue nevi whereas all other benign lesions, including common blue
nevi, were negative. In malignant melanomas MMP-9 was variably expressed in the pure and
invasive radial growth phase but not in the vertical growth phase [90].
Analyzing MMP-9 expression and the pathological parameters, we observed that MMP-9
presented a statistical significant association between its labeling intensity and the presence
of necrosis (p=0,032), nuclear grade (p=0,09) and degree of pigmentation (p=0,008). Addition‐
ally, MMP-9 extension was significantly associated with the degree of pigmentation (p=0,003).
These characteristics are classically linked to higher tumoural aggressiveness and poor clinical
prognosis in these neoplasias. However, contrarily to the expected, the less aggressive
tumours, without necrosis, with a lower nuclear grade and elevated pigmentation degree,
showed a higher MMP-9 labeling. Even non consensual, some previous studies in melanoma
suggest the opposite [91-93]. In vitro, MMP-9 expression was present or could be induced only
in cell lines derived from advanced primary melanomas, and was absent in cell lines derived
from early stage primary lesions [94]. In other study, the authors showed that less aggressive
cell lines were unable to produce MMP-9 after treatment with either interleukin-1β (IL-1β) or
tumour necrosis factor α(TNF-α) [93]. In murine, integrin receptor α5β1 and extracellular
matrix fibronectin ligand interaction induce the invasive potential of B16F10 cells and MMP-9
induction is the downstream effectors in the process [95].
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In skin human melanoma, an involvement of MMP- 9 in invasion and metastatic growth, as
in the regulation of tumour growth and progress has been suggested, by modulation of the
levels of N-cadherin and PCNA [96]. Also, in human uveal melanomas, MMP-9 was associated
with the presence of necrosis, a high mitotic rate [62] and with metastization [11]. In opposition,
no correlation was found between MMP-9 immunoreactivity occurrence of metastases in cases
of human ocular melanomas [88]. It has been proposed that not the melanoma cells themselves,
but the tumour-surrounding host cells secrete MMP-9 in vivo, indicating that host-derived
MMP-9 plays an important role in melanoma metastasis formation [97].
In canine cutaneous melanocytic tumours, according to our results, early invasion seems to be
associated with de novo expression of MMP-9 by neoplastic melanocytes. The lack of association
with aggressiveness in malignant lesions could suggest that other factors are involved in tissue
degradation during later stages of tumour progression, as proposed in human melanocytic
tumours [90].
Summarizing, in our study, malignancy is associated with an increase of MMP-9 and a decrease
of MMP-2 expression. In malignant lesions, however, the aggressiveness, evaluated by nuclear
grade, seems to be associated with a decrese of MMP-9 and an increase of MMP-2 expression.
These results suggest that might occurs a switch in the MMP expression profile during tumour
progression, involving not only emergence of MMP expression but also its downregulation,
as described in human melanoma [93].
Nevertheless, further studies involving MMPs, their tissue inhibitors, and other regulation
factors and their correlation with prognostic are needed to clarify this subject in canine
melanocytic tumours.
5. Conclusion
Both MMP-2 and MMP-9 were expressed in the majority of tumours. Our results showed a
close relationship between their expression and tumour behavior. The differences observed
between benign and malignant melanocytic tumours may suggest that MMP-2 and MMP-9
could be implicated in the progression of melanocytic precursor lesions to malignant mela‐
noma, although in an inverse manner, since MMP-2 is mainly found in melanocytomas and
MMP-9, on the other hand, is frequently absent in benign lesions. Therefore, our study suggests
that malignancy is associated with an increase of MMP-9 and a decrease of MMP-2 expression.
The association of MMP-2 with nuclear grade could indicate its role in tumour agressiveness.
Understanding MMPs regulation in melanoma provides new platforms to develop efficient
therapies. For that reason, more studies concerning MMPs and their regulators are needed in
order to deepen the knowledge about this enzymes, regarding their potential as prognostic
markers and future therapeutic targets in several cancers, including melanoma.
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